Dr. Craig H. Moskowitz, MD

Expert Publications

• High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
• Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
• Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
• Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
• Mantle cell lymphomas.
• Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
• Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
• Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
• CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen.
• Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
• High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
• Controversies in the treatment of lymphoma with autologous transplantation.

Media Releases

Get to know Hematologist-Oncologist Dr. Craig H. Moskowitz, who serves patients in Miami, Florida.

Dr. Moskowitz is an internationally recognized leader in lymphoma clinical research and treatment, specializing in the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.

As the Physician-in-Chief of the Oncology Service Line at the University of Miami Sylvester Comprehensive Cancer Center, he is responsible for the development, implementation, and administration of high quality, value-based oncology care at the main campus and satellites. He works across departments to improve the multidisciplinary care of cancer patients. 

As the leader of the Site Disease Groups, Dr. Moskowitz collaborates with group directors to enhance the patient navigation system and fosters multidisciplinary participation in the development and piloting of clinical trials.

Teaching students, he serves as a Professor within the Department of Medicine, Division of Medicine at the University of Miami Leonard M. Miller School of Medicine.

In regards to his educational background, Dr. Moskowitz graduated with his Bachelor of Science degree from Brooklyn College in 1980. He then went on to earn his medical degree from the Wayne State University School of Medicine in 1988.

Furthering his training, he performed his residency in internal medicine at Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses) in 1992, and his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in 1995.

Licensed to practice medicine in Florida and New York, the doctor is board-certified in medical oncology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Practice-changing, Dr. Moskowitz’s research focuses on improving the outcomes of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma. It has led to changes in the international standard of care for lymphoma patients. 

One area of accomplishment has been to optimize high-dose therapy and autologous stem cell transplantation, as well as new agents, to improve “salvage” therapy for patients with disease that has returned or is not responding to standard therapy. His second area of accomplishment has been to develop strategies that optimize the treatment of newly diagnosed DLBCL patients, according to the likelihood of their disease recurring. These include designing risk-adapted therapies, based on risk factors present before treatment and also the results of imaging studies. 

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Having been recognized for his research on a national level through multiple awards, Dr. Moskowitz has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is a member of the research council at MSKCC, and on the steering committees for the bi-annual international lymphoma conference in Lugano and the international Hodgkin lymphoma conference in Cologne.

Recommended Articles

• Ovarian Cancer Survivor Raises Awareness with Frozen Yogurt

  For almost all women in Gulfport, Mississippi, it’s business as usual. The daily, weekly, and monthly concerns of most women are occasionally interrupted by concerns about their bodies, but over a lifetime of navigating womanhood, it seldom crosses their minds past the immediate moment. The same...

• Investigating Lumps in Your Breasts

  If you have felt a new breast lump that is the same or increasing in size gradually, it is always wise to show this to your health care professional. They will then do a series of tests to investigate if you have a benign lump or breast cancer. Diagnosing and treating early will give you a better...

• Advancements in Lymphedema Surgery After Breast Cancer

  Until now, many were relatively unaware that it is possible to treat severe cases of lymphedema with surgery, and the results are shown to be quite effective.What is lymphedema?Lymphedema is a chronic condition that is characterized by discomfort that results from lymph fluid collecting around where...

• How #Cancerland Changed New York Fashion Week

  New York Fashion Week is a prestigious event that is held every year in the months of February and September. It shows off the latest fashion collections from renown designers, exhibited by the world’s most successful models. This year, AnoOno came together with #Cancerland, a U.S. non-profit...

• New Treatment for Difficult To Treat Type of Ovarian Cancer

  Ovarian clear cell carcinoma is one of the most difficult forms of ovarian cancers to treat, but there may be a new approach for therapy. The potential new form of therapy was discovered by Wistar scientists and discussed in detail in the online medical journal, Nature Cell Biology.Between 5 and 10...

• Everything You Need to Know About Biopsy Procedures

  What is a biopsy?A biopsy is a medical procedure, which is mostly used in diagnosing cancer. In this procedure, a small tissue sample is taken from your body for a closer examination under the microscope. A biopsy is usually recommended by your doctor if initial tests in your body suggest an...